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SUMMARY 
One recurring theme in drug development is to exploit synthetic lethal 
properties as means to preferentially damage the DNA of cancer cells. 
Others and we have previously developed inhibitors of the ATR kinase, and 
shown are particularly genotoxic for cells expressing certain oncogenes. In 
contrast, the mechanisms of resistance to ATR inhibitors remain 
unexplored. We here report on a genomewide CRISPR-Cas9 screen, which 
identified CDC25A as a major determinant of sensitivity to ATR inhibition. 
CDC25A deficient cells resist high doses of ATR inhibitors, which we show 
is due to their failure to prematurely enter mitosis in response to the drugs. 
Forcing mitotic entry with WEE1 inhibitors restores the toxicity of ATR 
inhibitors in CDC25A deficient cells. With ATR inhibitors now entering the 
clinic, our work provides a better understanding of the mechanisms by 
which these compounds kill cells, and reveals genetic interactions that 
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INTRODUCTION 
Targeting DNA repair enzymes is an active area of drug development in cancer 
therapy. The interest was fueled by the discovery of synthetic lethal interactions, 
such as the selective toxicity of polyADP-rybosil transferase (PARP) inhibitors for 
cells lacking BRCA tumor suppressors (Bryant et al., 2005; Farmer et al., 2005). 
One widespread feature of cancer cells is the presence of replication stress (RS), 
which is driven by the underlying oncogenes and is responsible for a large fraction 
of the genomic rearrangements found in cancer cells (Halazonetis et al., 2008; 
Lecona and Fernandez-Capetillo, 2014). RS stands for the accumulation of 
ssDNA at stalled replication forks, which can promote the nucleolytic breakage of 
the fork and subsequent recombination events, as well as overall replication 
catastrophe through the exhaustion of ssDNA-binding proteins (Toledo et al., 
2013). In mammals, RS is sensed and suppressed by a signaling-cascade 
initiated by the ATR kinase (Cimprich and Cortez, 2008; Lopez-Contreras and 
Fernandez-Capetillo, 2010). Recent evidence has also revealed the existence of a 
backup pathway controlled by DNAPK and CHK1 kinases that limits ssDNA in 
conditions of limited ATR activity (Buisson et al., 2015). We previously 
hypothesized that targeting ATR should be particularly deleterious for cancer cells 
experiencing high levels of oncogene-induced RS. Accordingly, mice with reduced 
ATR levels are refractory to the development of various tumors (Murga et al., 
2011; Schoppy et al., 2012), and ATR inhibitors are preferentially toxic for cells 
expressing MYC or CYCE oncogenes, or lacking tumor suppressors such as ATM 
or P53 (Kwok et al., 2015; Reaper et al., 2011; Toledo et al., 2011). In addition, 
other cancer-associated conditions such as the use of the Alternative Lengthening 
of Telomeres (ALT) pathway for telomere maintenance also increase the 
sensitivity to ATR inhibitors (Flynn et al., 2015). In contrast to mutations that 
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RESULTS 
In order to develop genomewide CRISPR screens, we first developed 
murine embryonic stem (ES) cells carrying a doxyciclin (Dox)-inducible Cas9 
cDNA (ESCas9). We used a previously developed system whereby the Cas9 cDNA 
under the control of a tetracycline responsive operator (tetO) was placed at the 3’ 
untranslated region of the ubiquitously expressed Col1a1 locus, and the 
expression of the rtTA transactivator was driven by the ROSA26 promoter (Beard 
et al., 2006) (Figure 1A). This two-tier system provides a stringent expression of 
Cas9, thereby preventing nuclease activity until Dox addition. Two clones showing 
a clear Dox-inducible Cas9 expression were selected for further experiments 
(Figure 1B; Figure S1A,B). To determine the efficiency of CRISPR-Cas9 editing 
in these cells, we co-infected a clone of ESCas9 cells with lentiviruses expressing 
green fluorescent protein (GFP) and with lentiviruses expressing both a Gfp-
targeting sgRNA and blue fluorescent protein (BFP). After sorting and before the 
addition of Dox, cells expressing both GFP and BFP dominated the culture. 48 hr 
after Dox the GFP (but not BFP) signal started to decrease and was virtually 
absent by 5 days of treatment (Figure 1C). To further characterize the efficiency 
of the system at endogenous loci, 3 different lentiviruses carrying sgRNAs against 
P53 were used to independently infect ESCas9 cells. After infection, a Dox-
inducible reduction in P53 levels was detectable with all sgRNAs (Figure 1D). 
Together, these results revealed that ESCas9 cells provide a very efficient platform 
for obtaining nullyzygous mutations in primary mammalian cells by CRISPR-Cas9 
editing and prompted us to conduct forward genetic screenings using this system. 
 
To perform our screenings, we used a recently described library targeting 
19.150 mouse genes with 87.897 sgRNAs (Koike-Yusa et al., 2014). ESCas9 cells 
were infected with the library at a low MOI to enrich in cells carrying a single 
lentiviral copy and sorted for BFP expression (Figure S1C). Infected cells were 
subsequently treated with Dox for 10 days to induce CRISPR-mediated mutations. 
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screening for resistance against 6-thioguanine (6TG). 6TG is an inert compound, 
which is converted to toxic inside cells by the action of hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). 5 million cells from the mutagenized library 
were exposed to 20µM 6TG for 7 days, a time/dose at which no wild type (wt) 
ESCas9 cells survive. 4 out of 5 of the resistant clones that were isolated carried 
sgRNAs targeting Hprt (Table S1). Using this library, a second screening was 
performed exposing the cells for 9 days to 0.9 µM of an ATR inhibitor developed 
by our group in a previous chemical screen (ATRi) (Toledo et al., 2011), again a 
dose and time at which no wt cells survive. A 3-day treatment with 300nM ATRi 
suffices to kill all wt ESCas9 cells, so that our screening was performed at highly 
stringent conditions. 5 out of 7 of the resistant clones that could be isolated in this 
screen carried sgRNAs that targeted the phosphatase CDC25A (Table S1). To 
strengthen our observations, we generated a new library using an independent 
clone of ESCas9 cells and repeated the screen. In this case, 6 out of 6 of the 6TG-
resistant clones carried sgRNAs targeting Hprt (Table S1). As for ATRi, we 
obtained 16 resistant clones, 6 of which targeted Cdc25a. This second library also 
identified sgRNAs targeting Cnot8, a member of the CCR4-NOT deadenylase 
complex (Collart and Panasenko, 2012), in a large fraction of the resistant clones 
(6/16) (Table S1). Given the recurrence of Cdc25a-targeting sgRNAs in both 
libraries, we focused this study in understanding the mechanism by which 
CDC25A deficiency limits the toxicity of ATR inhibitors.     
 
To verify that CDC25A deficiency confers resistance to ATR inhibition we 
first analyzed CDC25A expression in 3 independent ATRi-resistant clones 
isolated from the screen. Western blotting revealed the absence of CDC25A 
protein expression in these cells (Figure 2A), all of which carried small deletions 
or mutations at the sequence of Cdc25a targeted by the sgRNA (Figure 2B). 
Multiple lines of evidence confirmed a high degree of resistance against ATR 
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all wt ESCas9 cells at doses above 300 nM, CDC25A-deficient cells were able to 
expand at doses up to 3 µM (Figure 2C). XTT viability assays confirmed the 
resistance of the mutant clones to ATRi (Figure 2D). Moreover, in all clones, 
CDC25A deficiency also conferred resistance to an independent ATR inhibitor 
(AZ-20) (Foote et al., 2013) and to the CHK1 inhibitor UCN-01 (Figure S2A). 
Finally, and to discard any potential off-target effects of the sgRNA identified in 
the screen, we generated additional CDC25A deficient cells by infecting ESCas9 
cells with lentiviruses expressing 4 independent sgRNA sequences targeting 
Cdc25a. After selection, all pools of infected cells acquired resistance to ATRi in 
response to Dox (Figure S2B). Consistent with our findings in mouse cells, 
CDC25A heterozygosity in HAP1 cells (Figure S2C-E) or its depletion by siRNA 
in 5 additional human cancer cell lines (Figure S2F,G) invariably led to resistance 
to ATRi. Finally, we also tested whether increased CDC25A expression enhanced 
the sensitivity to ATR inhibition. Indeed, CDC25A overexpression sensitized 
NIH3T3 cells to ATRi (Figure S2H,I). Moreover, CDC25A expression is highest in 
tumors which are already known to be particularly dependent on the ATR/CHK1 
response such as Burkitt lymphomas, acute lymphoblastic or myeloid leukemias 
and diffuse large B cell lymphomas (Figure S2J) (Derenzini et al., 2015; Kwok et 
al., 2015; Murga et al., 2011; Santos et al., 2014; Sarmento et al., 2015; Schoppy 
et al., 2012) Together, these results reveal that CDC25A levels determine the 
sensitivity of mammalian cells to ATR inhibitors. 
 
We next tried to address the mechanism by which loss of CDC25A 
promoted resistance to ATR inhibitors. First, we evaluated whether ATR inhibition 
generated RS and/or chromosomal breakage in CDC25A-deficient cells. To 
determine whether this was the case, we first analyzed replication dynamics in 
response to ATRi. In vertebrates, depletion of ATR leads to increased origin firing 
and, as a consequence, slower progression at each individual fork (Eykelenboom 
et al., 2013). Consistent with an increase in origin firing, chemical inhibition of 
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measured by High-Throughput Microscopy (HTM), which was however not 
affected by CDC25A deficiency (Figure 3A). Moreover, ATR inhibitors induced 
equivalent amounts of ssDNA in wt and Cdc25a-/- ESCas9 cells (Figure 3B). Next, 
we monitored the impact of ATR inhibition at individual replication forks by 
stretched DNA fiber analyses. Despite CDC25A-deficient cells presented a slightly 
lower density of replication forks in unchallenged conditions, the addition of ATRi 
increased origin firing and decreased fork rates in both wt and Cdc25a-/- ESCas9 
cells (Figure S3A,B). Surprisingly, and in contrast to the modest reduction 
observed in CDC25-deficient ESCas9 cells on the amount of ATRi-induced RS, 
chromosomal breakage induced by the drug was fully abrogated in Cdc25a-/- cells, 
measured by western blotting against γH2AX and RPA32-S4/8P (Figure 3C), as 
well as by quantifying γH2AX and 53BP1 nuclear foci by HTM (Figures 3D and 
S3C). Hence, despite ATR inhibitors generate RS in both wt and mutant cells, this 
is only translated into cytotoxic DNA double strand breaks (DSBs) in the presence 
of CDC25A. Whereas we cannot discard that some cell-death might be due to RS 
instead of DSB, we do not think that an altered RS-response or an intrinsic 
resistance to RS can account for the resistance to ATRi in CDC25A-deficient 
cells. Accordingly, Cdc25a-/- ESCas9 cells show normal levels of CHK1 
phosphorylation upon exposure to the RS-inducing agent hydroxyurea (HU) and 
are not resistant to this drug (Figure S3D,E).  
 
CDC25A was originally discovered as a mitosis promoting factor (Russell 
and Nurse, 1986), which promotes M-phase entry by eliminating inhibitory 
phosphorylations in CDK1 that are placed by the WEE1 kinase (Galaktionov and 
Beach, 1991). Later studies revealed that, in response to DNA damage, CHK1-
dependent phosphorylation of CDC25A targets it for degradation, thereby 
activating the checkpoints that limit the expansion of damaged cells (Falck et al., 
2001; Mailand et al., 2000; Peng et al., 1997; Sanchez et al., 1997). Hence, we 
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exposure to ATRi led to a dose-dependent increase in CDC25A levels in ESCas9 
cells (Figure S4A). Noteworthy, whereas we could validate that CNOT8 
deficiency renders ESCas9 cells resistant to ATRi, this phenotype was not linked to 
CDC25A expression (Figure S4B,C). 
 
Recent studies have indicated that the generation of DSBs by RS is due to 
un-replicated regions of the genome reaching mitosis (reviewed in (Mankouri et 
al., 2013)). Consistently, FACS analyses revealed that ATRi-induced γH2AX 
occurred in cells with a late G2/M DNA content, which was again absent in 
Cdc25a-/- ESCas9 cells (Figure 4A). Moreover, immunofluorescence analyses 
confirmed the presence of ATRi-induced γH2AX foci in mitotic cells, identified by 
the presence of H3-S10 phosphorylation, in wt but not in CDC25A-deficient cells 
(Figure 4B). We thus hypothesized that chromosomal breaks induced by ATR 
inhibitors could be due to a premature entry into M-phase of cells undergoing RS 
provoked by an increase of CDC25A levels. Supporting this view, FACS analyses 
revealed that ATR inhibitors promoted mitotic entry in ESCas9 cells, an effect that 
was largely abolished in CDC25A-deficient cells (Figure 4C). Noteworthy, a 
prolonged exposure to ATR inhibitors led to H3-S10 phosphorylation in wt cells 
with an S-phase DNA content, consistent with the premature activation of the 
mitotic kinases in cells still undergoing DNA replication. ATR inhibitors also induce 
some mitotic entry in Cdc25a-/- ESCas9 cells, albeit at later times and to a much 
lesser extent. Thus, whereas CDC25A upregulation is the main responsible for 
the premature mitotic entry induced by ATRi, ATR also limits mitotic entry through 
CDC25A-independent mechanisms. In this regard, and given the known roles of 
the CDC25A homologue CDC25B in the G2/M transition, we tested the impact of 
CDC25B deficiency in the response to ATR inhibitors. However, ATR inhibition did 
not increase the levels of CDC25B (Figure S4A), and CDC25B deletion in ESCas9 
cells or siRNA-mediated depletion in human cancer cell lines did not increase the 
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ATR inhibitors induce cell death, we recorded videos of H2B-eGFP expressing wt 
and Cdc25a-/- ESCas9 cells exposed to ATR inhibitors (Figure S4H). These 
analyses revealed that ATRi-induced cell death occurred frequently at mitosis or 
shortly during the following interphase. Interestingly, the low levels of cell death 
that are observed in CDC25A-deficient cells exposed to ATRi also tend to occur 
after passage through mitosis, suggesting that the same mechanism of ATRi-
induced cell killing applies to these cells.  
 
As final proof of this model, we forced mitotic entry in CDC25A-deficient 
cells by activating CDK1 through WEE1 inhibition. In agreement with our 
hypothesis, WEE1 inhibitors generated DSB and forced mitotic entry in CDC25A-
deficient cells (as measured by H2AX and H3S10 phosphorylation by western 
blotting) (Figure 4D). Moreover, WEE1 inhibitors sensitized CDC25A-deficient 
cells to ATR inhibitors (Figure 4E). Both WEE1 and ATR inhibitors reduced the 
inhibitory phosphorylation of CDK1 at Tyr15, particularly when combined together 
(Figure S4I). Of note, a prolonged exposure to ATRi reduced CDK1-Y15P levels 
even in CDC25A-deficient cells, consistent with our earlier observations 
suggesting that whereas CDC25A plays a central role, ATR can limit mitotic entry 
through CDC25A-dependent and -independent mechanisms. Altogether, the 
results presented here suggest that the toxicity of ATR inhibitors is due to a 
combination of (a) the generation of RS and (b) promoting the premature mitotic 
entry of cells bearing RS, where DNA breaks arise. Forced mitotic entry is a 
consequence of the premature activation of CDK1, which is largely mediated by 
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DISCUSSION 
We here report on a cellular platform for the development of forward 
genetic screenings in primary mammalian cells using CRISPR-Cas9, which we 
have used to identify mechanisms of resistance to ATR inhibitors. Two 
independent screenings identified sgRNAs targeting Cdc25a and Cnot8 that 
conferred resistance to these compounds. Whereas this study focused on 
CDC25A given that it is a well-known oncogene (Ray and Kiyokawa, 2008), we 
also confirmed the resistance to ATRi in the Cnot8 mutant clones isolated from 
the screening; although to a lesser extent to that observed in CDC25A deficient 
cells. Given the pleotropic roles of the CCR4-NOT complex on RNA metabolism, 
its link to ATR biology remains to be determined although it seems independent 
from CDC25A since ATRi-induced CDC25A upregulation occurs normally in 
CNOT8-deficient cells (Figure S4C). In what regards to CDC25A, this oncogene 
is frequently overexpressed in various cancers, which we suggest could confer 
sensitivity to ATR inhibitors. Whereas reduced levels of CDC25A emerge as a 
mechanism of resistance to ATR inhibitors in cancer therapy remains to be seen, 
our findings also suggest that CDC25A levels could be used to identify patients 
more likely to respond to this therapy. Supporting this view, CDC25A levels 
correlate with the sensitivity to ATRi in the human cancer cell lines used in this 
study (Figure S2E,G) and, as mentioned before, CDC25A expression is highest 
in tumors known to be sensitive to ATRi (Figure S2J).  
 
In what regards to the use of ATR inhibitors for cancer therapy, our work 
indicates that a combination with WEE1 inhibitors could overcome such a 
resistance, and suggests the potential of ATRi/WEE1i drug combinations. Along 
these lines, a recent work has identified that WEE1 inhibitors are preferentially 
toxic for cancer cells with low levels of the ribonucleotide reductase subunit RRM2 
(Prister et al., 2015), which has been recently shown to be key for the essential 
roles of ATR in mammalian cells (Buisson et al., 2015; Lopez-Contreras et al., 
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should synergize not only with other RS-inducing drugs such as cisplatin or 
gemcitabine (Prevo et al., 2012; Vendetti et al., 2015), but also with other 
strategies that promote mitotic entry. 
 
Finally, our work sheds light into the mechanisms of cell killing by ATR 
inhibitors. The results presented illustrate that the toxicity of these compounds is a 
combination of two activities: (a) their capacity to induce RS, and (b) to force 
premature mitotic entry. This second activity is not present in other RS-inducing 
chemotherapeutic drugs, which might offer an advantage to ATR inhibitors in 
certain conditions. Bringing cells with RS into mitosis would promote the cleavage 
of stalled forks and the subsequent generation of toxic DSBs. This model is 
consistent with recent data showing that RS is converted into DSB during mitosis 
(Minocherhomji et al., 2015). Interestingly, a prolonged exposure of ATR inhibitors 
leads to the phosphorylation of mitotic markers such as H3S10 in cells with a DNA 
content lower than G2 (Figure 4C). Thus, premature mitosis might occur as early 
as in S-phase, which would support earlier observations of replication catastrophe 
induced by ATR inhibitors (Toledo et al., 2013). 
 
 In summary, our work provides proof-of-principle of the value of ESCas9 
cells as an efficient platform for CRISPR-Cas9 based genomewide screenings, 
clarifies the mechanism by which ATR inhibitors kill cells, and has led to the 
identification of CDC25A as a potential biomarker to optimize the rational use of 
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EXPERIMENTAL PROCEDURES 
Generation of ESCas9 cells 
The previously described KH2 ES cell line (Beard et al., 2006) contains an frt-
flanked neomycin resistance gene and an ATG-less hygromycin resistance gene 
without promoter at the Col1a1 locus. In addition, this cell line also contains an 
M2rtTA transactivator targeted at the endogenous Rosa26 locus. A Flp-dependent 
recombination event using the pBS31 plasmid provides a PGK promoter and a 
ATG initiation codon to the hygromycin gene as well as the gene of interest under 
a tetO minimal promoter into the Col1a1 locus. This recombination eliminates the 
neomycin resistance gene and confers a new resistance to the successfully 
targeted cell. Thus, to generate the ESCas9 cells, KH2 cells were electroporated 
with pBS31-Cas9 and a plasmid encoding for Flp. 24-48 hours after 
electroporation, cells were incubated with 140µg/ml of hygromycin to select cells 
in which recombination took place. Resistant clones were picked, amplified and 
tested for Dox-inducible Cas9 expression. 
 
Generation of genomewide mutant libraries and screening 
Two independent genomewide mutant libraries were generated with two different 
ESCas9 clones, as previously described (Koike-Yusa et al., 2014) with minor 
modifications. Briefly, 5x106 ESCas9 cells were infected in suspension for one hour 
at 37ºC with the genomewide lentiviral library at a MOI (multiplicity of infection) of 
0.3 and plated on a fresh layer of feeder cells. Three days after the infection, a 
total of 2x106 BFP-positive cells (estimated library coverage of 20X) were sorted 
and cultured to establish each of the cell libraries. Next, we maintained a 
minimum of 5x106 cells (estimated library coverage of 50X) with 2 µg/ml of 
doxycycline for a total of 10 days to induce Cas9 expression allowing gene 
editing. To perform the 6-thioguanine (6-TG) screening, a total of untreated or 
doxycycline-treated 5x106 cells were incubated with 6-TG at 20µM for 7 days. 
Resistant clones were picked and amplified on culture media without 6-TG. To 
perform the ATR inhibitor (ATRi) screening, a total of untreated or doxycycline-
treated 5x106 mESCs were incubated with ATRi (0.9 µM) for 9 days. Resistant 
clones were picked and amplified on culture media with ATRi (0.3 µM) for 5 
additional days before using culture media without ATRi. The ATRi used in these 
study was found in a screening reported previously (Toledo et al., 2011). To 
identify the sgRNA sequences inserted in the resistant mESC clones, we 
amplified by PCR the fragment flanking the U6-sgRNA cassette from the lentiviral 
vector, sub-cloned it in a TOPO vector and sequenced by Sanger sequencing 
(see Table S1 for sgRNA sequences). Finally, to generate newly deficient mESCs 
for CDC25A or CDC25B, we independently infected ESCas9 cells with at least three 
different lentiviral supernatants encoding specifically designed sgRNAs targeting 
either cdc25a or cdc25b. After infection, the pool of ESCas9 cells, usually infected 
with a percentage above the 90% of efficiency, was divided in two and either 
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before performing experiments. See the Supplemental Information for a full list 
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FIGURE LEGENDS 
Figure 1. Efficient and Dox-inducible gene knockouts in ESCas9 cells.  
(A) Scheme illustrating the two-allele system used for the generation of ESCas9 
cells. In this previously described system(Beard et al., 2006), the Cas9 cDNA is 
placed under the control of a tet-responsible sequence (tetO) at the Col1a1 
locus. At the same time, the reverse tetracycline-controlled transactivator (rtTA) 
is expressed from the Rosa26 locus, providing Dox-inducible-activation of Cas9 
expression.  
(B) Levels of Cas9 mRNA evaluated by RT-PCR (normalized to levels of 
GAPDH mRNA) in the 2 clones of ESCas9 cells used in this study. The high 
stringency of the system prevents cleavage in the absence of Dox. Data are 
represented as mean  s.d. (n=3). See also Figure S1A,B. 
(C) FACS analysis illustrating the loss of GFP signal in ESCas9 cells that were 
made GFP positive by infection with a lentiviral construct expressing GFP, and 
simultaneously infected with a lentivirus expressing a Gfp-targeting sgRNA 
together with BFP. Doubly infected cells are thus BFP and GFP positive, and 
gradually lose GFP expression after the addition of Dox. See also Figure S1C. 
(D) Western blot illustrating the Dox-dependent loss of P53 expression 
observed in ESCas9 cells that were infected with lentiviruses expressing 3 
independent P53-targeting sgRNAs. TUBULIN levels are shown as a loading 
control. Dox was used at 2 µg/ml. 
 
Figure 2. Resistance to ATR inhibition in CDC25A-deficient ESCas9 cells. 
(A) Western blot illustrating the loss of CDC25A expression in 3 independent 
ATRi-resistant clones.  
(B) Examples of the mutations in Cdc25a identified in ATRi-resistant ESCas9 
cells shown in (A). Note that all mutations include small insertions or deletions 
that change the reading frame in exon 2, precisely at the 3’ of the sgRNA 
sequence (in red). 
(C) Representative pictures of the resistance to ATRi observed in CDC25A-
deficient ESCas9 cells exposed to the compound for 72 hr. ES cells are grown on 
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top of a feeder layer of growth-arrested MEF, which are unaffected by the 
treatment. Scale bar (white) indicates 25 µm.  
(D) XTT viability assay in wild type and CDC25A-deficient ESCas9 cells exposed 
to ATRi for 24 hr at the indicated doses. Data are representative of 3 
independent experiments. Error bars indicate s.d. See also Figure S2. 
 
Figure 3. ATR inhibition generates RS but not DSB in CDC25A-deficient 
cells. 
(A) HTM analysis of the EdU signal per individual nucleus in wild type (WT) and 
CDC25A-deficient ESCas9 cells exposed to ATRi for 1 hr (900 nM). 
(B) HTM analysis of the BrdU signal accumulated in ssDNA per individual 
nucleus in wild type (WT) and CDC25A-deficient ESCas9 cells exposed to ATRi 
for 4 hr (900 nM). 
(C) WB illustrating the levels of H2AX (γH2AX) and RPA (S4/8) phosphorylation 
in WT and CDC25A-deficient ESCas9 cells exposed to ATRi for 4 hr (0, 0.3, 0.9, 
2 and 3 µM). TUBULIN and total RPA levels are shown as loading controls. 
(D) HTM analysis of the γH2AX signal per individual nucleus in WT and 
CDC25A-deficient ESCas9 cells treated (or not) with ATRi (0.3, 0.9 and 2 µM; 4 
hr). See also Figure S3. 
 
Figure 4. ATRi induces premature mitotic entry and DNA breakage in a 
CDC25A-dependent manner.  
(A) Representative FACS profiles showing the distribution of γH2AX-positive 
cells (x, DNA content; y, γH2AX) of WT and CDC25A-deficient ESCas9 cells 
exposed to ATRi (900 nM) for the indicated times. Numbers indicate the 
percentage of γH2AX-positive cells (red) in each case.  
(B) Representative image of the presence of DSBs in mitotic ESCas9 cells 
exposed to ATRi for 4 hr (300 nM). Mitotic cells were identified by antibodies 
against pH3S10 (red). DSBs were identified by γH2AX (green) foci. DAPI was 
used to stain DNA. Numbers in white indicate the percentage of pH3S10-
positive cells presenting γH2AX foci. Scale bar (white) indicates 2.5 µm. 
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(C) Representative FACS profiles showing the distribution of pH3S10-positive 
cells (x, DNA content; y, pH3S10) of WT and CDC25A-deficient ESCas9 cells 
exposed to ATRi (900 nM) for the indicated times. Numbers indicate the 
percentage of pH3S10-positive cells (red) in each case.  
(D) WB illustrating the levels of H2AX (γH2AX), RPA (S4/8) and H3 (S10) 
phosphorylation in WT and CDC25A-deficient ESCas9 cells exposed to ATRi 
(300 nM) and/or WEE1i (100 or 300 nM) for 4 hr. An antibody detecting 
phosphorylated CDK substrates was also used as measure of overall CDK 
activity. TUBULIN and total RPA levels are shown as loading controls. 
 (E) Representative pictures of cultures of WT and CDC25A-deficient ESCas9 
cells exposed to ATRi (300 nM) and/or WEE1i (100 nM) for 72 hr. Scale bar 
(white) indicates 25 µm. See also Figure S4. 
 
 
 
 
 
  
 




